Christian Angermayer, the German financier who founded psychedelic-medicine companies Compass Pathways and ATAI Life Sciences, marked this week’s ATAI Beckley corporate news with a sweeping personal essay — and an unusually candid account of where the movement now stands.
“Psychedelics needed an evangelist ten years ago,” he wrote. “Now it is all about commercialization.”
Angermayer framed the shift as a change of mission. A decade ago, he said, the field “needed someone like me willing to convince the world.” Today, “the world is largely convinced,” and the new task is “to get these medicines into the hands of millions of patients around the globe as quickly as possible.”
He was just as direct about the money. Running through the common threads he sees across his ventures — which span psychedelics, Bitcoin, longevity, brain-computer interfaces, and AI — Angermayer listed one without euphemism: “There is massive financial upside.” The ideas with the most potential to improve humanity, he argued, “often also offer the largest economic opportunity, because their addressable markets are, in many cases, almost limitless.”
The figures underline the point. Angermayer said he personally invested “well over $100 million” into ATAI, and that ATAI and Compass together “raised more than $1.5 billion,” taking both companies public on Nasdaq.
The essay interlaces that commercial ambition with spiritual language — psychedelics, he wrote, “allow us to reconnect with The Divine and with ourselves” — before closing on a line that reads equally as a market forecast: “The future is psychedelic, and it is here.”For a field that has long presented itself in the language of healing, it was a candid look at the business underneath — from one of its principal architects.